Solid Bioscience Stock Price, News & Analysis

Solid Biosciences presented data on AAV-SLB101, a novel AAV vector for Duchenne gene therapy SGT-003, at the ESGCT Congress in October 2022. The data showed AAV-SLB101's superior transduction efficiency and biodistribution to muscle cells in studies across various models compared to AAV9. Notably, AAV-SLB101 led to significantly higher microdystrophin expression in muscles while reducing liver distribution. The company plans to submit an IND for SGT-003 by mid-2023 and initiate patient dosing in late-2023, aiming for improved safety and efficacy in treatment.

Solid Biosciences has reported promising one-year data from its IGNITE DMD Phase I/II clinical trial evaluating the microdystrophin gene therapy SGT-001. Patients showed an average improvement in stride velocity 95th centile (SV95C) of 8.8%-9.5% compared to baseline, indicating better ambulatory function. As a real-world assessment tool validated by the European Medicines Agency, SV95C revealed significant enhancements over control and natural history patient data. The results are being showcased at the 27th World Muscle Society Congress in Halifax, Nova Scotia.

Solid Biosciences (Nasdaq: SLDB) announced a merger with AavantiBio to create a precision genetic medicine company targeting neuromuscular and cardiac rare diseases. This strategic acquisition aims to leverage synergies from their product candidates, including SGT-003 for Duchenne muscular dystrophy and AVB-202 for Friedreich’s ataxia. The combined company will have approximately $215 million in cash, expected to fund operations into 2025. Leadership will transition to Bo Cumbo, CEO of AavantiBio, post-approval by Solid stockholders.

Solid Biosciences (Nasdaq: SLDB) announced participation in two investor conferences focused on Duchenne muscular dystrophy. Co-Founder and CEO Ilan Ganot, along with Chief Scientific Officer Carl Morris, will hold a fireside chat at the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 3:00 PM ET, and at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 1:00 PM ET. Live webcasts will be available on the company’s investor relations website, with replays accessible post-event.

Solid Biosciences (Nasdaq: SLDB) reported second-quarter financial results for 2022, indicating a net loss of $25.1 million, up from $18.7 million in the same period in 2021. The company generated $6.2 million in collaboration revenue, a rise from $3.6 million year-over-year. As of June 30, 2022, Solid had $162.9 million in cash, ensuring funding until Q2 2024. The company is advancing its gene therapy programs, SGT-001 and SGT-003, with patient dosing expected to continue in 2023 and an IND submission anticipated for SGT-003 in mid-2023.

Solid Biosciences (Nasdaq: SLDB) announced its participation in two significant conferences focusing on Duchenne muscular dystrophy therapies. At the PPMD 2022 Annual Conference from June 23-26 in Scottsdale, AZ, Chief Scientific Officer Carl Morris will discuss gene therapy approaches on June 24 at 11:30 a.m. EDT. Subsequently, at the ICNMD 2022 in Brussels from July 5-9, Perry Shieh will present selected abstracts on July 7 at 10:30 a.m. ET. Solid Biosciences is dedicated to developing innovative treatments like SGT-001 and SGT-003 to address Duchenne at its genetic source.

Solid Biosciences (Nasdaq: SLDB) announced the grant of inducement awards to Mark Tucker, PhD, as part of his appointment as Senior Vice President, Quality. This was approved by the independent board on April 25, 2022. Dr. Tucker received an option to purchase 120,000 shares of common stock at an exercise price of $0.57, along with a restricted stock unit for 60,000 shares. Both awards will vest over four years based on continued employment. Solid Biosciences focuses on therapies for Duchenne muscular dystrophy, including its gene therapy candidates SGT-001 and SGT-003.

Solid Biosciences Inc. (Nasdaq: SLDB) has announced participation in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 a.m. ET. Ilan Ganot, CEO, and Carl Morris, Chief Scientific Officer, will represent the company. A live webcast will be available on the investor relations website, with a replay accessible after the event. Solid Biosciences is dedicated to developing transformative treatments for Duchenne muscular dystrophy, focusing on gene therapy candidates SGT-001 and SGT-003.

Solid Biosciences (Nasdaq: SLDB) announced its participation in two significant conferences focused on Duchenne muscular dystrophy. At the ASGCT Annual Meeting (May 16-19, 2022), Chief Scientific Officer Carl Morris will present data from the Phase I/II IGNITE DMD clinical trial of SGT-001 gene therapy, including updated long-term outcomes. Following this, Morris will attend the CureDuchenne 2022 FUTURES National Conference (May 27-29, 2022) to discuss advancements in gene therapy. For more details, visit their website.